For termination of section by section 2007(a) of Puspan. L. 117–180, see Effective and Termination Dates note below.

2022—Par. (9). Puspan. L. 117–180, § 2002(1)(A), substituted “premarket notification submissions, and de novo classification requests” for “and premarket notification submissions” in introductory provisions.

Par. (9)(D). Puspan. L. 117–180, § 2002(1)(B), substituted “submissions, and de novo classification requests” for “and submissions”.

Par. (9)(F). Puspan. L. 117–180, § 2002(1)(C), substituted “premarket notification submissions, and de novo classification requests” for “and premarket notification submissions”.

Par. (9)(G), (H). Puspan. L. 117–180, § 2002(1)(D), substituted “submissions, or requests” for “or submissions”.

Par. (9)(K). Puspan. L. 117–180, § 2002(1)(E), substituted “premarket notification submissions, or de novo classification requests” for “or premarket notification submissions”.

Par. (11). Puspan. L. 117–180, § 2002(2), substituted “2021” for “2016”.

2017—Par. (8). Puspan. L. 115–52, § 202(a)(2), added par. (8). Former par. (8) redesignated (9).

Par. (9). Puspan. L. 115–52, § 202(a)(1), redesignated par. (8) as (9). Former par. (9) redesignated (10).

Par. (10). Puspan. L. 115–52, § 202(a)(1), (3), redesignated par. (9) as (10) and substituted “submissions, and de novo classification requests” for “and submissions” in subpar. (D). Former par. (10) redesignated (11).

Par. (11). Puspan. L. 115–52, § 202(a)(1), (4), redesignated par. (10) as (11) and substituted “2016” for “2011”.

Pars. (12) to (14). Puspan. L. 115–52, § 202(a)(1), redesignated pars. (11) to (13) as (12) to (14), respectively.

2016—Par. (5). Puspan. L. 114–255 substituted “360e(d)(5)” for “360e(d)(6)”.

2012—Par. (9). Puspan. L. 112–144, § 202(1), struck out “incurred” after “expenses” in introductory provisions.

Par. (10). Puspan. L. 112–144, § 202(2), substituted “October 2011” for “October 2001”.

Par. (13). Puspan. L. 112–144, § 202(3), substituted “is registered (or is required to register) with the Secretary under section 360 of this title because such establishment is engaged in the manufacture, preparation, propagation, compounding, or processing of a device.” for “is required to register with the Secretary under section 360 of this title and is one of the following types of establishments:” and struck out subpars. (A) to (C) which related to manufacturer, single-use device reprocessor, and specification developer establishments.

2007—Puspan. L. 110–85, § 211(1), substituted “For purposes of this subpart” for “For purposes of this part” in introductory provisions.

Pars. (5) to (9). Puspan. L. 110–85, § 211(2), (3), added pars. (5) to (7) and redesignated former pars. (5) and (6) as (8) and (9), respectively. Former pars. (7) and (8) redesignated (10) and (12), respectively.

Par. (10). Puspan. L. 110–85, § 211(2), (4), redesignated par. (7) as (10) and substituted “October of the preceding fiscal year” for “April of the preceding fiscal year” and “October 2001” for “April 2002”.

Par. (11). Puspan. L. 110–85, § 211(5), added par. (11).

Par. (12). Puspan. L. 110–85, § 211(2), redesignated par. (8) as (12).

Par. (13). Puspan. L. 110–85, § 211(6), added par. (13).

2004—Puspan. L. 108–214, § 2(d)(3)(A), made technical correction to directory language of Puspan. L. 107–250, § 102(a), which enacted this section.

Par. (4)(B). Puspan. L. 108–214, § 2(a)(1)(A), substituted “and for which substantial clinical data are necessary to provide a reasonable assurance of safety and effectiveness” for “and for which clinical data are generally necessary to provide a reasonable assurance of safety and effectiveness”.

Par. (4)(D). Puspan. L. 108–214, § 2(a)(1)(B), struck out “manufacturing,” after “software,”.

Par. (5)(J). Puspan. L. 108–214, § 2(a)(1)(C), substituted “a premarket application or premarket report under section 360e of this title or a premarket application under section 262 of title 42.” for “a premarket application under section 360e of this title or section 262 of title 42.”

Par. (8). Puspan. L. 108–214, § 2(a)(1)(D), substituted “The term ‘affiliate’ means a business entity that has a relationship with a second business entity (whether domestic or international)” for “The term ‘affiliate’ means a business entity that has a relationship with a second business entity”.

Amendment by Puspan. L. 117–180 effective Oct. 1, 2022, with fees under this subpart to be assessed for all submissions listed in section 379j(a)(2)(A) of this title received on or after Oct. 1, 2022, see section 2008 of Puspan. L. 117–180, set out as a note under section 360d of this title.

Puspan. L. 115–52, title II, § 209, Aug. 18, 2017, 131 Stat. 1020, provided that: “The amendments made by this title [see section 201(a) of Puspan. L. 115–52, set out as a Short Title of 2017 Amendment note under section 301 of this title] shall take effect on October 1, 2017, or the date of the enactment of this Act [Aug. 18, 2017], whichever is later, except that fees under part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 379i et seq.] shall be assessed for all submissions listed in section 738(a)(2)(A) of such Act [21 U.S.C. 379j(a)(2)(A)] received on or after October 1, 2017, regardless of the date of the enactment of this Act.”

Puspan. L. 112–144, title II, § 206, July 9, 2012, 126 Stat. 1007, provided that: “The amendments made by this title [enacting section 379d–3 of this title, amending this section and sections 360e, 379j, and 379j–1 of this title, and repealing provisions set out as notes under this section] shall take effect on October 1, 2012, or the date of the enactment of this Act [July 9, 2012], whichever is later, except that fees under part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act [this subpart] shall be assessed for all submissions listed in section 738(a)(2)(A) of such Act [21 U.S.C. 379j(a)(2)(A)] received on or after October 1, 2012, regardless of the date of the enactment of this Act.”

Puspan. L. 110–85, title II, § 216, Sept. 27, 2007, 121 Stat. 852, provided that: “The amendments made by this subtitle [subtitle A (§§ 211–217) of title II of Puspan. L. 110–85, enacting section 379j–1 of this title and amending this section and section 379j of this title] shall take effect on October 1, 2007, or the date of the enactment of this Act [Sept. 27, 2007], whichever is later, except that fees under part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act [this subpart] shall be assessed for all premarket applications, premarket reports, supplements, 30-day notices, and premarket notification submissions received on or after October 1, 2007, regardless of the date of the enactment of this Act.”

Puspan. L. 110–85, title II, § 217, Sept. 27, 2007, 121 Stat. 852, which provided that the amendments by sections 211 to 217 of Puspan. L. 110–85 (amending this section and section 379j of this title) would cease to be effective Oct. 1, 2012, and that section 379j–1 of this title would cease to be effective Jan. 31, 2013, was repealed by Puspan. L. 112–144, title II, § 207(span)(1), July 9, 2012, 126 Stat. 1007.

Puspan. L. 117–180, div. F, title II, § 2007(a), Sept. 30, 2022, 136 Stat. 2154, provided that: “Sections 737 and 738 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379i; 379j) shall cease to be effective October 1, 2027.”

Puspan. L. 115–52, title II, § 210(a), Aug. 18, 2017, 131 Stat. 1020, which provided that this section and section 379j of this title would cease to be effective Oct. 1, 2022, was repealed by Puspan. L. 117–180, div. F, title II, § 2007(c), Sept. 30, 2022, 136 Stat. 2154.

[Puspan. L. 117–180, div. F, title II, § 2007(c), Sept. 30, 2022, 136 Stat. 2154, provided that the repeal of section 210(a) of Puspan. L. 115–52, formerly set out above, is effective Oct. 1, 2022.]

Puspan. L. 112–144, title II, § 207(a), July 9, 2012, 126 Stat. 1007, which provided that sections 737 and 738 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379i; 379j) would cease to be effective Oct. 1, 2017, and that section 738A (21 U.S.C. 379j–1) of the Federal Food, Drug, and Cosmetic Act (regarding reauthorization and reporting requirements) would cease to be effective Jan. 31, 2018, was repealed by Puspan. L. 115–52, title II, § 210(c), Aug. 18, 2017, 131 Stat. 1020.

[Puspan. L. 115–52, title II, § 210(c), Aug. 18, 2017, 131 Stat. 1020, provided that the repeal of section 207(a) of Puspan. L. 112–144, formerly set out above, is effective Oct. 1, 2017.]

Puspan. L. 107–250, title I, § 106, Oct. 26, 2002, 116 Stat. 1602, provided that: “The amendments made by this title [enacting this subpart] shall take effect on the date of the enactment of this Act [Oct. 26, 2002], except that fees shall be assessed for all premarket applications, premarket reports, supplements, and premarket notification submissions received on or after October 1, 2002, regardless of the date of enactment.”

Puspan. L. 107–250, title I, § 107, Oct. 26, 2002, 116 Stat. 1602, which provided that the amendments made by title I of Puspan. L. 107–250 (enacting this subpart) would cease to be effective Oct. 1, 2007, except that section 103 of Puspan. L. 107–250, set out as a note below, would cease to be effective Jan. 31, 2008, was repealed by Puspan. L. 112–144, title II, § 207(c)(1), July 9, 2012, 126 Stat. 1007.

[Puspan. L. 112–144, title II, § 207(c), July 9, 2012, 126 Stat. 1007, provided that the repeal of section 107 of Puspan. L. 107–250, formerly set out above, is effective Sept. 30, 2007.]

Puspan. L. 117–180, div. F, title II, § 2009, Sept. 30, 2022, 136 Stat. 2155, provided that: “Notwithstanding the amendments made by this title [amending this section and sections 379j and 379j–1 of this title and repealing provisions set out as notes under this section and section 379j–1 of this title], part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379i et seq.), as in effect on the day before the date of the enactment of this title [Sept. 30, 2022], shall continue to be in effect with respect to the submissions listed in section 738(a)(2)(A) of such Act [21 U.S.C. 379j(a)(2)(A)] (as defined in such part as of such day) that on or after October 1, 2017, but before October 1, 2022, were received by the Food and Drug Administration with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2023.”

Puspan. L. 115–52, title II, § 208, Aug. 18, 2017, 131 Stat. 1019, provided that: “Notwithstanding the amendments made by this title [see section 201(a) of Puspan. L. 115–52, set out as a Short Title of 2017 Amendment note under section 301 of this title], part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379i et seq.), as in effect on the day before the date of the enactment of this title [Aug. 18, 2017], shall continue to be in effect with respect to the submissions listed in section 738(a)(2)(A) of such Act [21 U.S.C. 379j(a)(2)(A)] (as defined in such part as of such day) that on or after October 1, 2012, but before October 1, 2017, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2018.”

Puspan. L. 112–144, title II, § 205, July 9, 2012, 126 Stat. 1007, provided that: “Notwithstanding the amendments made by this title [enacting section 379d–3 of this title, amending this section and sections 360e, 379j, and 379j–1 of this title, and repealing provisions set out as notes under this section], part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379i et seq.), as in effect on the day before the date of the enactment of this title [July 9, 2012], shall continue to be in effect with respect to the submissions listed in section 738(a)(2)(A) of such Act [21 U.S.C. 379j(a)(2)(A)] (in effect as of such day) that on or after October 1, 2007, but before October 1, 2012, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2013.”

Puspan. L. 110–85, title II, § 214, Sept. 27, 2007, 121 Stat. 852, provided that: “Notwithstanding section 107 of the Medical Device User Fee and Modernization Act of 2002 (Public Law 107–250) [formerly set out as an Effective and Termination Dates note above], and notwithstanding the amendments made by this subtitle [subtitle A (§§ 211–217) of title II of Puspan. L. 110–85, enacting section 379j–1 of this title and amending this section and section 379j of this title], part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379i et seq.), as in effect on the day before the date of the enactment of this subtitle [Sept. 27, 2007], shall continue to be in effect with respect to premarket applications, premarket reports, premarket notification submissions, and supplements (as defined in such part as of such day) that on or after October 1, 2002, but before October 1, 2007, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2008.”

Puspan. L. 117–180, div. F, title II, § 2001(span), Sept. 30, 2022, 136 Stat. 2147, provided that: “Congress finds that the fees authorized under the amendments made by this title [amending this section and sections 379j and 379j–1 of this title and repealing provisions set out as notes under this section and section 379j–1 of this title] will be dedicated toward expediting the process for the review of device applications and for assuring the safety and effectiveness of devices, as set forth in the goals identified for purposes of part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379i et seq.), in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record.”

Puspan. L. 115–52, title II, § 201(span), Aug. 18, 2017, 131 Stat. 1013, provided that: “The Congress finds that the fees authorized under the amendments made by this title [see section 201(a) of Puspan. L. 115–52, set out as a Short Title of 2017 Amendment note under section 301 of this title] will be dedicated toward expediting the process for the review of device applications and for assuring the safety and effectiveness of devices, as set forth in the goals identified for purposes of part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act [this subpart] in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record.”

Puspan. L. 112–144, title II, § 201(span), July 9, 2012, 126 Stat. 1002, provided that: “The Congress finds that the fees authorized under the amendments made by this title [enacting section 379d–3 of this title, amending this section and sections 360e, 379j, and 379j–1 of this title, and repealing provisions set out as notes under this section] will be dedicated toward expediting the process for the review of device applications and for assuring the safety and effectiveness of devices, as set forth in the goals identified for purposes of part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act [this subpart] in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record.”

Puspan. L. 110–85, title II, § 201(c), Sept. 27, 2007, 121 Stat. 842, provided that: “The Congress finds that the fees authorized under the amendments made by this title [enacting section 379j–1 of this title and amending this section and sections 333, 360, 360i, 360m, 374, and 379j of this title] will be dedicated toward expediting the process for the review of device applications and for assuring the safety and effectiveness of devices, as set forth in the goals identified for purposes of part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 379i et seq.] in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record.”

Puspan. L. 107–250, title I, § 101, Oct. 26, 2002, 116 Stat. 1589, provided that: “The Congress finds that—

Puspan. L. 107–250, title I, § 103, Oct. 26, 2002, 116 Stat. 1600, as amended by Puspan. L. 109–43, § 2(span), Aug. 1, 2005, 119 Stat. 441, provided that:

Puspan. L. 107–250, title I, § 104(span), Oct. 26, 2002, 116 Stat. 1601, directed the Secretary of Health and Human Services to conduct a study for the purpose of making certain determinations regarding the medical device user-fee program established under the amendment made by section 102 of Puspan. L. 107–250 and to submit a report to Congress by Jan. 10, 2007.

Puspan. L. 107–250, title I, § 105, Oct. 26, 2002, 116 Stat. 1601, provided that: